Lantheus Holdings, Inc. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Lantheus Holdings, Inc. is a radiopharmaceutical-focused company operating in three primary categories: Radiopharmaceutical Oncology (led by PYLARIFY), Precision Diagnostics (led by DEFINITY), and Strategic Partnerships. The company operates as a single business segment.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenues | $378.0 million | $394.1 million | $750.8 million | $764.1 million |
| Gross Profit | $241.0 million | $255.8 million | $478.7 million | $497.6 million |
| Operating Income | $88.0 million | $102.7 million | $190.0 million | $209.4 million |
| Net Income | $78.8 million | $62.1 million | $151.7 million | $193.1 million |
| Diluted EPS | $1.12 | $0.88 | $2.14 | $2.74 |
| Cash & Equivalents | $695.6 million (as of June 30, 2025) | |||
| Long-Term Debt | $566.8 million (net of current portion) | |||
| Operating Cash Flow (YTD) | $194.7 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 4.1% in Q2 and 1.7% YTD compared to 2024. This was primarily driven by a decrease in the net sales price of PYLARIFY (due to the expiration of Transitional Pass-Through (TPT) status on Dec 31, 2024) and lower sales volume of TechneLite.
- Product Performance:
- PYLARIFY: Revenue declined 8.3% in Q2 and 4.5% YTD.
- DEFINITY: Revenue increased 7.5% in Q2 and 5.5% YTD, driven by higher sales volumes.
- Strategic Partnerships: Revenue increased 32.8% in Q2 and 46.6% YTD, aided by CDMO revenue from the Evergreen acquisition and milestone payments.
- Expense Fluctuations:
- G&A Expenses: Increased 40.3% in Q2 and 29.4% YTD, largely due to the April 2025 acquisition of Evergreen Theragnostics (including nonrecurring stock award settlements and professional fees).
- R&D Expenses: Decreased 24.9% in Q2 and 24.7% YTD. The decrease is attributed to the absence of large upfront option payments made in 2024 (e.g., $36.0M to Life Molecular, $28.0M to Perspective), partially offset by a $10.0M payment to AstraZeneca in May 2025.
- Investment Gains/Losses: The company recorded a significant unrealized gain of $14.6 million in Q2 2025 on equity securities (primarily Perspective Therapeutics), compared to an unrealized loss of $22.5 million in Q2 2024.
Guidance, Outlook, and Material Events
- Acquisitions:
- Evergreen Theragnostics: Acquired on April 1, 2025, for an upfront cash payment of $276.4 million, with up to $727.5 million in potential milestone payments. This adds CDMO capabilities and the LNTH-2501 asset.
- Life Molecular Imaging: Acquired on July 21, 2025 (subsequent event), for $350.0 million upfront plus up to $400.0 million in milestones. Includes the Alzheimer's diagnostic Neuraceq.
- Divestiture: Entered an agreement on May 1, 2025, to sell its SPECT business (including TechneLite and NEUROLITE) to SHINE Technologies. Assets are classified as "held for sale" ($73.4 million).
- Regulatory & Pipeline:
- PYLARIFY: FDA accepted a New Drug Application (NDA) for a new formulation on August 6, 2025, with a PDUFA date of March 6, 2026. The company is seeking TPT status for the new formulation.
- MK-6240: Met co-primary endpoints in pivotal studies; NDA submission expected in Q3 2025.
- NAV-4694: NDA submission expected in 2026.
- Capital Allocation:
- Repurchased $100.0 million of common stock in Q2 2025 under the 2024 Program.
- On July 31, 2025, the Board authorized a new $400.0 million share repurchase program through December 31, 2027.
- Risks: Key risks include the impact of the expiration of TPT status on PYLARIFY pricing and market share, potential generic competition in 2026, and the successful integration of recent acquisitions.
Investor Verification Checklist
- Reimbursement Impact: Verify the actual impact of the CMS 2025 OPPS Rule on PYLARIFY net pricing and market share relative to competitors retaining TPT status.
- Acquisition Integration: Monitor the integration progress and cost synergies of the Evergreen and Life Molecular acquisitions, specifically regarding CDMO revenue ramp-up.
- SPECT Divestiture: Confirm the closing timeline and final proceeds of the SPECT business sale to SHINE Technologies.
- Pipeline Milestones: Track the acceptance and approval status of the new PYLARIFY formulation NDA and the MK-6240 NDA submission in Q3 2025.
- Debt Covenants: Review compliance with the 2022 Revolving Facility covenants (Interest Coverage Ratio and Net Leverage Ratio) given the significant cash outflows for acquisitions.